Literature DB >> 34728084

Early experience with donation after circulatory death heart transplantation using normothermic regional perfusion in the United States.

Deane E Smith1, Zachary N Kon2, Julius A Carillo3, Stacey Chen3, Claudia G Gidea4, Greta L Piper5, Alex Reyentovich4, Robert A Montgomery6, Aubrey C Galloway3, Nader Moazami3.   

Abstract

OBJECTIVE: This pilot study sought to evaluate the feasibility of our donation after circulatory death (DCD) heart transplantation protocol using cardiopulmonary bypass (CPB) for normothermic regional reperfusion (NRP).
METHODS: Suitable local DCD candidates were transferred to our institution. Life support was withdrawn in the operating room (OR). On declaration of circulatory death, sternotomy was performed, and the aortic arch vessels were ligated. CPB was initiated with left ventricular venting. The heart was reperfused, with correction of any metabolic abnormalities. CPB was weaned, and cardiac function was assessed at 30-minute intervals. If accepted, the heart was procured with cold preservation and transplanted into recipients in a nearby OR.
RESULTS: Between January 2020 and January 2021, a total of 8 DCD heart transplants were performed: 6 isolated hearts, 1 heart-lung, and 1 combined heart and kidney. All donor hearts were successfully resuscitated and weaned from CPB without inotropic support. Average lactate and potassium levels decreased from 9.39 ± 1.47 mmol/L to 7.20 ± 0.13 mmol/L and 7.49 ± 1.32 mmol/L to 4.36 ± 0.67 mmol/L, respectively. Post-transplantation, the heart-lung transplant recipient required venoarterial extracorporeal membrane oxygenation for primary lung graft dysfunction but was decannulated on postoperative day 3 and recovered uneventfully. All other recipients required minimal inotropic support without mechanical circulatory support. Survival was 100% with a median follow-up of 304 days (interquartile range, 105-371 days).
CONCLUSIONS: DCD heart transplantation outcomes have been excellent. Our DCD protocol is adoptable for more widespread use and will increase donor heart availability in the United States.
Copyright © 2021 The American Association for Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  donation after circulatory death; heart transplantation; normothermic regional perfusion

Mesh:

Year:  2021        PMID: 34728084     DOI: 10.1016/j.jtcvs.2021.07.059

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   6.439


  5 in total

1.  Cellular recovery after prolonged warm ischaemia of the whole body.

Authors:  David Andrijevic; Zvonimir Vrselja; Taras Lysyy; Shupei Zhang; Mario Skarica; Ana Spajic; David Dellal; Stephanie L Thorn; Robert B Duckrow; Shaojie Ma; Phan Q Duy; Atagun U Isiktas; Dan Liang; Mingfeng Li; Suel-Kee Kim; Stefano G Daniele; Khadija Banu; Sudhir Perincheri; Madhav C Menon; Anita Huttner; Kevin N Sheth; Kevin T Gobeske; Gregory T Tietjen; Hitten P Zaveri; Stephen R Latham; Albert J Sinusas; Nenad Sestan
Journal:  Nature       Date:  2022-08-03       Impact factor: 69.504

Review 2.  Normothermic Regional Perfusion is an Emerging Cost-Effective Alternative in Donation After Circulatory Death (DCD) in Heart Transplantation.

Authors:  Emad Alamouti-Fard; Pankaj Garg; Ishaq J Wadiwala; John H Yazji; Mohammad Alomari; Md Walid Akram Hussain; Mohamed S Elawady; Samuel Jacob
Journal:  Cureus       Date:  2022-06-29

3.  Commentary: Hope on the horizon: Heart transplantation with donation after circulatory death.

Authors:  Jennie H Kwon; Arman Kilic
Journal:  JTCVS Tech       Date:  2022-02-21

4.  Logistics for expanding heart transplantation from donation after circulatory death using normothermic regional perfusion.

Authors:  Nader Moazami; Deane Smith; Aubrey Galloway
Journal:  JTCVS Tech       Date:  2022-01-21

Review 5.  Heart Donation and Preservation: Historical Perspectives, Current Technologies, and Future Directions.

Authors:  Nicholas R Hess; Luke A Ziegler; David J Kaczorowski
Journal:  J Clin Med       Date:  2022-09-28       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.